Soleus Capital Management’s Damora Therapeutics, Inc. Ordinary Shares DMRA Stock Holding History

Soleus Capital Management’s Portfolio DMRA Stock Details DMRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-35,906	Closed	-$646K	–	89
2023 Q3	$646K	Sell	35,906 -4,094	-10%	-$161K	0.06%	85
2023 Q2	$2.52M	Buy	+40,000	New	+$2.18M	0.28%	66
2021 Q3	–	Sell	-21,526	Closed	-$2.72M	–	77
2021 Q2	$2.72M	Sell	21,526 -38,980	-64%	-$5.31M	0.42%	42
2021 Q1	$9.19M	Hold	60,506	–	–	1.66%	12
2020 Q4	$18.9M	Buy	+60,506	New	+$22.5M	2.5%	4

Other funds holding DMRA

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Soleus Capital Management's DMRA Position: Q4 2023 in Review

Soleus Capital Management sold out of Damora Therapeutics, Inc. Ordinary Shares (DMRA) in Q4 2023, closing a stake of 35,906 shares — an estimated $646K sold.

Soleus Capital Management first reported a position in DMRA in Q4 2020 and held it in 5 quarters. The position peaked at $18.9M in Q4 2020. 21 funds tracked by Wall St. Rank hold DMRA as of Q4 2023.

Soleus Capital Management reported no remaining Damora Therapeutics, Inc. Ordinary Shares position as of Q4 2023 after selling out during the quarter.
Soleus Capital Management sold 35,906 Damora Therapeutics, Inc. Ordinary Shares shares in Q4 2023, an estimated $646K.
Soleus Capital Management first reported a position in Damora Therapeutics, Inc. Ordinary Shares in Q4 2020 and held it in 5 quarters.
Soleus Capital Management's Damora Therapeutics, Inc. Ordinary Shares position peaked at $18.9M in Q4 2020.
21 funds tracked by Wall St. Rank held Damora Therapeutics, Inc. Ordinary Shares as of Q4 2023.

Based on Soleus Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.